Literature DB >> 33844363

A recurrent MORC2 mutation causes Charcot-Marie-Tooth disease type 2Z.

Dragan Vujovic1, David R Cornblath2, Steven S Scherer1.   

Abstract

We found a p.Ala406Val (c.1217C > T) mutation in MORC2 in three individuals, from two families. All three individuals were evaluated and clinical electrophysiology was completed. The neuropathy began in childhood to early adulthood, with distal weakness progressing to proximal weakness. Vinblastine (for Hodgkin lymphoma) acutely worsened the weakness in one patient. This finding confirms that that the p.Ala406Val mutation in MORC2 causes severe neuropathy. In addition, we report the first case of vinblastine neurotoxicity in Charcot-Marie-Tooth disease type 2Z.
© 2021 Peripheral Nerve Society.

Entities:  

Keywords:  Charcot-Marie-Tooth disease; axonal CMT; neuropathy; vinblastine

Mesh:

Substances:

Year:  2021        PMID: 33844363      PMCID: PMC8544607          DOI: 10.1111/jns.12443

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   5.188


  13 in total

1.  Characterization of molecular mechanisms underlying the axonal Charcot-Marie-Tooth neuropathy caused by MORC2 mutations.

Authors:  Paula Sancho; Luca Bartesaghi; Olivia Miossec; Francisco García-García; Laura Ramírez-Jiménez; Anna Siddell; Elisabet Åkesson; Eva Hedlund; Petra Laššuthová; Samuel I Pascual-Pascual; Teresa Sevilla; Marina Kennerson; Vincenzo Lupo; Roman Chrast; Carmen Espinós
Journal:  Hum Mol Genet       Date:  2019-05-15       Impact factor: 6.150

2.  De novo p.T362R mutation in MORC2 causes early onset cerebellar ataxia, axonal polyneuropathy and nocturnal hypoventilation.

Authors:  Ginevra Zanni; Marta Nardella; Sabina Barresi; Emanuele Bellacchio; Marcello Niceta; Andrea Ciolfi; Stefano Pro; Stefano D'Arrigo; Marco Tartaglia; Enrico Bertini
Journal:  Brain       Date:  2017-06-01       Impact factor: 13.501

3.  Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort.

Authors:  Arya Shah; E Matthew Hoffman; Michelle L Mauermann; Charles L Loprinzi; Anthony J Windebank; Christopher J Klein; Nathan P Staff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-02-08       Impact factor: 10.154

4.  Hyperactivation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2.

Authors:  Iva A Tchasovnikarova; Richard T Timms; Christopher H Douse; Rhys C Roberts; Gordon Dougan; Robert E Kingston; Yorgo Modis; Paul J Lehner
Journal:  Nat Genet       Date:  2017-06-05       Impact factor: 38.330

5.  Cytosolic functions of MORC2 in lipogenesis and adipogenesis.

Authors:  Beatriz Sánchez-Solana; Da-Qiang Li; Rakesh Kumar
Journal:  Biochim Biophys Acta       Date:  2013-11-25

6.  Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease.

Authors:  Teresa Sevilla; Vincenzo Lupo; Dolores Martínez-Rubio; Paula Sancho; Rafael Sivera; María J Chumillas; Mar García-Romero; Samuel I Pascual-Pascual; Nuria Muelas; Joaquín Dopazo; Juan J Vílchez; Francesc Palau; Carmen Espinós
Journal:  Brain       Date:  2015-10-24       Impact factor: 13.501

7.  MORC2 mutations cause axonal Charcot-Marie-Tooth disease with pyramidal signs.

Authors:  Obaid M Albulym; Marina L Kennerson; Matthew B Harms; Alexander P Drew; Anna H Siddell; Michaela Auer-Grumbach; Alan Pestronk; Anne Connolly; Robert H Baloh; Stephan Zuchner; Stephen W Reddel; Garth A Nicholson
Journal:  Ann Neurol       Date:  2016-01-13       Impact factor: 10.422

8.  De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial Dysmorphism.

Authors:  Maria J Guillen Sacoto; Iva A Tchasovnikarova; Erin Torti; Cara Forster; E Hallie Andrew; Irina Anselm; Kristin W Baranano; Lauren C Briere; Julie S Cohen; William J Craigen; Cheryl Cytrynbaum; Nina Ekhilevitch; Matthew J Elrick; Ali Fatemi; Jamie L Fraser; Renata C Gallagher; Andrea Guerin; Devon Haynes; Frances A High; Cara N Inglese; Courtney Kiss; Mary Kay Koenig; Joel Krier; Kristin Lindstrom; Michael Marble; Hannah Meddaugh; Ellen S Moran; Chantal F Morel; Weiyi Mu; Eric A Muller; Jessica Nance; Marvin R Natowicz; Adam L Numis; Bridget Ostrem; John Pappas; Carl E Stafstrom; Haley Streff; David A Sweetser; Marta Szybowska; Melissa A Walker; Wei Wang; Karin Weiss; Rosanna Weksberg; Patricia G Wheeler; Grace Yoon; Robert E Kingston; Jane Juusola
Journal:  Am J Hum Genet       Date:  2020-07-20       Impact factor: 11.025

9.  Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability.

Authors:  M J Ibañez-Juliá; G Berzero; G Reyes-Botero; T Maisonobe; T Lenglet; M Slim; S Louis; A Balaguer; M Sanson; E Le Guern; P Latour; D Ricard; T Stojkovic; D Psimaras
Journal:  Acta Oncol       Date:  2017-12-15       Impact factor: 4.089

10.  Dimerization of MORC2 through its C-terminal coiled-coil domain enhances chromatin dynamics and promotes DNA repair.

Authors:  Hong-Yan Xie; Tai-Mei Zhang; Shu-Yuan Hu; Zhi-Ming Shao; Da-Qiang Li
Journal:  Cell Commun Signal       Date:  2019-12-03       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.